Atlas Trials

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Clinical trial NCT04970043 · UNKNOWN

Trial details

NCT number
NCT04970043
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Lung Cancer Stage II
Start date
2021-07-31
Primary completion
2024-07-30
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.